Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Orchestrating CRO Services
From our January 1 issue: In a clinical trial, a CRO may provide a brief solo (a niche service) or the whole symphony (preclinical to post-approval services).
- The drug development process is vast, involving a nearly symphonic coordination of many disparate players—trial sponsors, contract research organizations (CROs), and institutions such as academic medical centers and hospitals. Each of these players adds a distinct part to an integrated whole. Over the past two decades, sponsors ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.